NBIX

Neurocrine Biosciences (NBIX) is the lead sponsor of 17 active clinical trials listed on ClinicalTrials.gov^[4], including 13 Phase 3^[1], 3 Phase 2^[2], 1 Phase 4^[3].

Trial NCT07196501^[5] evaluates NBI-1065845 in Major Depressive Disorder with a target enrollment of 550 participants. Trial NCT06963034^[6] evaluates NBI-1117568 in Schizophrenia with a target enrollment of 284 participants. Trial NCT04400331^[7] evaluates Valbenazine in Chorea, Huntington with a target enrollment of 154 participants.

No Form 4 insider filings for NBIX were recorded at the SEC in the past 30 days^[8].